Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company